GlassScriptPhysician profile
Margaret E Hagan
NPI 1114922887
$4,120.54
in general payments reported to CMS, 2019-2025
32 companies · $648 in 2025
The $648 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $248 · 2021: $256 · 2022: $598 · 2023: $743 · 2024: $1,054 · 2025: $648.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,428 · Consulting Fee: $16.33.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,428.25 |
| Consulting Fee | $16.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Insmed, INC. | $683.39 | 2019-2025 | Arikayce, Brinsupri |
| Merck Sharp & Dohme LLC | $506.68 | 2019-2025 | Zerbaxa, Dificid, Recarbrio |
| Abbvie INC. | $413.27 | 2019-2025 | |
| Melinta Therapeutics, LLC | $369.08 | 2019-2025 | Kimyrsa, Vabomere, Rezzayo |
| Takeda Pharmaceuticals U.S.A., INC. | $257.42 | 2022-2025 | Hyqvia, Cuvitru |
| Hospira, INC. | $167.45 | 2024-2025 | |
| Paratek Pharmaceuticals, INC. | $157.07 | 2023-2025 | Nuzyra |
| Gilead Sciences, INC. | $146.87 | 2019-2024 | |
| Shionogi INC | $143.68 | 2022-2025 | Fetroja |
| Octapharma USA, INC. | $143.20 | 2023-2025 | Panzyga, Octagam Immune Globulin (Human) |
| Aimmune Therapeutics, INC. | $130.68 | 2024-2025 | Vowst |
| Smith+Nephew, INC. | $128.21 | 2020-2022 | |
| Csl Behring | $103.06 | 2022-2025 | Hizentra |
| Pfizer INC. | $85.60 | 2023-2025 | |
| Ferring Pharmaceuticals INC. | $77.98 | 2022-2024 | Rebyota |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Viiv Healthcare Company | $77.51 | 2019-2023 | Dovato, Cabenuva |
| Allergan, INC. | $73.74 | 2019-2020 | |
| Shire North American Group INC | $63.27 | 2019 | |
| Tetraphase Pharmaceuticals, INC. | $62.23 | 2019-2025 | |
| Grifols USA, LLC | $59.20 | 2023-2024 | Xembify |
| Astellas Pharma US INC | $44.83 | 2023 | Cresemba |
| Adma Biomanufacturing LLC | $36.25 | 2021-2023 | |
| Astrazeneca Pharmaceuticals LP | $30.80 | 2022-2023 | Evusheld |
| Davol INC. | $25.90 | 2023 | Arista Ah Flexitip |
| La Jolla Pharmaceutical Company | $24.88 | 2024 | Xacduro |
| Nestle Healthcare Nutrition INC. | $22.04 | 2023 | |
| Mayne Pharma Commercial LLC | $20.23 | 2022 | |
| Dynavax Technologies Corporation | $18.05 | 2025 | Heplisav-B |
| Pharming Healthcare, INC. | $16.72 | 2022 | |
| Convatec INC. | $15.87 | 2023 | |
| Vyera Pharmaceuticals, LLC | $15.38 | 2021 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Margaret Hagan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.